The metabotropic glutamate receptors (mGluRs) have been predicted to have a classical seven transmembrane domain structure similar to that seen for members of the G-protein-coupled receptor (GPCR) superfamily. However, the mGluRs (and other members of the family C GPCRs) show no sequence homology to the rhodopsinlike GPCRs, for which this seven transmembrane domain structure has been experimentally confirmed. Furthermore, several transmembrane domain prediction algorithms suggest that the mGluRs have a topology that is distinct from these receptors. In the present study, we set out to test whether mGluR5 has seven true transmembrane domains. Using a variety of approaches in both prokaryotic and eukaryotic systems, our data provide stong support for the proposed seven transmembrane domain model of mGluR5. We propose that this membrane topology can be extended to all members of the family C GPCRs.
1
The mGluRs modulate synaptic transmission and neuronal excitability throughout the peripheral and central nervous system. They have been classified into three groups based on sequence homology, pharmacology, and signal transduction coupling. Group I mGluRs, consisting of mGluR1 and mGluR5, uniformly couple to phospholipase C, while group II and III mGluRs, composed of mGluR2, mGluR3, mGluR4, mGluR6, mGluR7, and mGluR8, inhibit adenylyl cyclase activity in heterologous expression systems (1, 2) .
Since their cloning, the structure-function relationships of mGluRs have garnered extensive interest. Relatively recent classification of G-protein-coupled receptors (GPCRs) has categorized mGluRs as family C GPCRs characterized structurally by a large N-terminal extracellular domain and consisting of mGluRs, GABA B receptors, Ca 2ϩ -sensing receptors, and certain pheromone receptors. The large N-terminal extracellular domain of mGluRs exhibits distant homology to bacterial amino acid periplasmic binding proteins, suggesting the domain is responsible for ligand binding (3) . Structural modeling of mGluRs based on this homology accurately predicts important residues for ligand binding (4) . Exchange of this domain among mGluRs also endows specific ligand binding properties (5) (6) (7) . Recently, crystal structure determination of the N-terminal domain with bound ligand has definitively confirmed its role in ligand binding and conformational changes of the domain with binding have made several predictions for potential mechanisms for receptor activation (8) .
While the structure of the ligand binding N-terminal domain has been clearly resolved, little data exists on the structure and membrane topology of the subsequent transmembrane domains. The complete structure of the canonical GPCR, rhodopsin, has recently been solved and confirms a long line of studies delineating seven membrane spanning ␣-helices (9 -12) . Based on sequence homology, this structure can minimally be extended to other family A GPCRs, such as ␤-adrenergic receptors, where independent studies also espouse seven transmembrane (7TM) domains (13, 14) . However, the application of the rhodopsin topology to non-homologous GPCRs, such as mGluRs, requires experimental confirmation. For example, some studies have recently suggested that family B bradykinin B2 receptors, may possess five transmembrane domains with two re-entrant loops (15) .
Mutagenesis and chimera studies of mGluRs have delineated specific functional roles for the hydrophilic loops between putative transmembrane domains and the C-terminal cytoplasmic domain (16 -18) . These studies bear implications for topology models. A set of studies has determined that each of the mGluR cytoplasmic regions contributes to G-protein coupling, but only the second intracellular loop determines G-protein specificity (16) . Interestingly, the third intracellular loop rather than the second delineates G-protein specificity in other GPCRs. Several potential phosphorylation sites have been determined through mutagenesis studies in the first and second intracellular loops and the C-terminal domain (18, 19) . However, no direct biochemical evidence of phosphorylation has been obtained at any of these sites. Protease protection of in vitro translated mGluR1 and mGluR interaction sites for cytoplasmic proteins, such as calmodulin and Homer, definitively identify the cytoplasmic location of the C-terminal domain (20 -24) . Taken together, the structure-function studies of mGluRs to date definitively pinpoint the N-terminal domain as extracellular and the second intracellular loop and C-terminal domain as intracellular, while some data suggest a cytoplasmic location for the first and third intracellular loops. * This work was supported by Grant MH60230 from the National Institutes of Health and the Gillson-Longenbaugh Foundation (to R. W. G.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ These authors contributed equally to this work. A number of different prediction algorithms are available for use in predicting the transmembrane topology of receptors. The most commonly used of these include classical hydrophobicity mapping and more modern methods that utilize hidden Markov modeling approaches (25) . These approaches applied to bovine rhodopsin (accession number AAA30674), predict seven transmembrane domains that coincide with the transmembrane domains identified by crystallographic studies (9) (Fig.  1) . However, similar approaches applied to mGluRs yield equivocal results, frequently failing to select the domain identified as putative transmembrane domain 3 when mGluRs are forced to a seven transmembrane domain model (Fig. 1) . Thus, while application of a seven transmembrane domain topology to mGluRs makes intuitive sense given that the receptor couples to heterotrimeric G-proteins, a less biased approach to predicting membrane topology clearly indicates that experimental evaluation of this model is needed.
In this study, we directly address mGluR topology with truncated fusion constructs of mGluR5a in prokaryotic and eukaryotic expression systems to probe the capability of individual hydrophobic domains to traverse the membrane. Our data confirm that all seven putative hydrophobic domains span the membrane.
EXPERIMENTAL PROCEDURES
Computerized Transmembrane Domain Prediction-The KyteDoolittle algorithm was applied to the full rat mGluR5a and bovine rhodopsin sequences using the TopPred web site (bioweb.pasteur.fr/ seqanal/interfaces/toppred.html) (26) . The parameters used were: Full window size: 21; Core window size: 11; Wedge window size: 5; for eukaryotic proteins. Additional analyses were performed using the TMHMM hidden Markov model for predicting transmembrane helices in protein sequences (v2.0; www.cbs.dtu.dk/services/TMHMM-2.0/) (27) . The images used for Fig. 1b are taken directly from the output of this web site.
Cloning-mGluR5a was cloned into the pCI:Neo expression vector. SalI restriction sites were introduced at amino acid residues 608 (i1), 641 (e1), 688 (i2), 728 (e2), 769 (i3), 799 (e3), and 869 using a modification of the Stratagene QuickChange mutagenesis procedure as previously described (18) . These SalI sites were used for insertion of all eptiopes used in this study. In all cases, the amino acid listed is changed to a Val and the following residue is changed to an Asp (the amino acids encoded by the SalI restriction site G/TCGAC). This allowed for inframe fusion of proteins with a similar SalI or XhoI site introduced in-frame or of paired primers with SalI or XhoI overhangs. FLAG epitopes were inserted using large synthetic primers including the FLAG epitope and SalI and XhoI overhangs. FLAG or HA epitopes were also inserted in place of amino acids 22-27 (just downstream of the signal sequence) by inserting a SalI site at amino acid 22 and an MluI site at amino acid 27, followed by insertion of the FLAG epitope or HA epitope made with large synthetic primers including 5Ј-SalI and 3Ј-MluI overhangs. All constructs were verified by direct sequencing.
Glycosylation Site Determination-Consensus sites for N-linked glycosylation (NX(S/T)) were mutated by a substitution of the N residues making the following changes: N88G (native glycosylation site 1), N209A (native glycosylation site 2), N377L (native glycosylation site 3), N381A (native glycosylation site 4), N444G (native glycosylation site 5), and N733G (native glycosylation site 6). These mutations were made in combination to generate the ⌬NG construct. Mutants in which only individual glycosylation sites remain are denoted NG(no.) (NG5 and NG6), with no. indicating the consensus glycosylation site that has not been mutated, while all others were eliminated as mentioned above. All constructs were confirmed by sequencing the entire open reading frame of the constructs.
For analysis of recombinant mGluR5, COS7 cells obtained from ATCC (Manassas, VA) were cultured in humidified 5% CO 2 incubators in Dulbecco's modified Eagle's medium with GlutaMAX supplemented with 10% fetal bovine serum and transfected with wild-type and glycosylation variants of mGluR5 using LipofectAMINE 2000 (Invitrogen Life Technologies, Carlsbad, CA) under optimized conditions. In brief, liposomal/DNA complexes formed at room temperature using a ratio of 1 g of DNA to 1 l of liposomes in 100 l of serum-free OptiMem (Invitrogen Life Technologies) for 20 min were added to cells at 80 -90% confluency. For experiments involving inhibition of glycosylation with tunicamycin, following 2 h incubation with liposomal/DNA complexes cell cultures were washed with 10% fetal bovine serum, Dulbecco's modified Eagle's medium and tunicamycin added to the culture medium at a final concentration of 10 g/ml. In all cases cells were harvested in 2% SDS with a cell scraper during the peak protein expression interval, 24 -36 h post-transfection. Sample protein concentration was determined using the BioRad DC protein assay.
Equal amounts of protein as calculated by protein assay were loaded onto 6% polyacrylamide gels and electrophoresed at a constant voltage of 20 V through the stacking gel and 200 V through the resolving gel. Electrophoresis was stopped after ϳ2.5 h, a runtime determined empirically to yield the optimal resolution for the mobility shift observed FIG. 1. Transmembrane domain prediction models applied to mGluR5a and bovine rhodopsin. Panel A shows the Kyte-Doolittle algorithm for determining hydrophobicity of membrane proteins. The domains originally assigned as transmembrane domains 1-7 in mGluR5 and those identified as bona fide transmembrane domains in rhodopsin are indicated above the plot. Panel B shows the TMHMM analysis algorithm applied to mGluR5a and bovine rhodopsin. Red regions indicated possible transmembrane domains with the relative probability of each indicated on the Y axis. Pink and blue regions denote predicted extracellular and intracellular domains, respectively. Note that this algorithm predicts that the region denoted TM3 is not a transmembrane domain in mGluR5a, whereas the predicted structure of rhodopsin has clearly seven transmembrane domains.
between glycosylated and unglycosylated forms of mGluR5. Proteins were transferred onto nitrocellulose membrane support by use of a semidry blotter at a constant current of 200 mA for 2.5 h. After transfer, membranes were blocked in 4% nonfat dry milk for 1 h. Membranes were exposed to rabbit serum raised against a peptide (CSSPKYDTLI-IRDYTNSSSSL) corresponding to the mGluR5 C terminus at a 1:2000 dilution in 4% nonfat dry milk for 1 h at room temperature. Following three 20 min washes in phosphate-buffered saline, membranes were rocked in goat anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody in 4% nonfat dry milk at a 1:5000 dilution for 1 h at room temperature. Following three 20 min washes in phosphate-buffered saline, immunoreactivity was visualized using ECL chemiluminescence reagent (Amersham Biosciences, Piscataway, NJ) and exposure to BioMax MR film (Kodak). Optimal exposure time was determined for individual experiments.
mGluR5-Lactamase Fusion Construct Ampicillin Resistance-The ␤-lactamase open reading frame was PCR-amplified without its signal sequence from pBluescript and fused with the various SalI mutants to create fusion constructs terminating at each putative transmembrane domain. These fusion constructs were cloned into a modified pET-28a vector in which the N-terminal His and T7 tags were deleted by digestion with NcoI-BamHI followed by blunting and ligation.
The final constructs were transformed into the E. coli strain BL21-DE3-RP (Stratagene) for expression. The cells were grown overnight at 37°C to saturation in LB ϩ 2% glucose ϩ 30 g/ml kanamycin ϩ 34 g/ml chloramphenicol. 5 l of 10-fold serial dilutions were spotted onto LB agar plates with 2% glucose, 30 g/ml kanamycin, 34 g/ml chloramphenicol, 10 g/ml ampicillin, and 100 M isopropyl-1-thio-␤-D-galactopyranoside and allowed to grow overnight at 37°C to test for ampicillin resistance.
Live Staining of mGluR5a-transfected COS7 Cells-Truncated mGluR5-GFP fusion proteins were created by cloning an EcoRI-SalI fragment from the mGluR5 SalI mutants into the pEGFP-N3 vector (Clontech). In-frame mGluR5a GFP fusions were constructed by cloning a PCR amplified GFP opening reading frame (without the stop codon) with SalI and XhoI overhangs into the mGluR5 SalI mutants.
24 to 48 h post-transfection, media was removed, cells were washed once with 100 mM Hepes pH 7.4 and treated with 100 mM Hepes ϩ 3% BSA for GFP immunostaining or with 100 mM Hepes for FLAG immunostaining for 10 min at room temperature. Cells were then cooled to 4°C and incubated with chicken anti-GFP primary antibody (Chemicon, 1:250) diluted in 100 mM Hepes ϩ 3% BSA or monoclonal anti-FLAG antibody (M2, Sigma, 1:50) diluted in 100 mM Hepes for 30 min. After five quick rinses with 100 mM Hepes ϩ 3% BSA, cells were incubated with goat anti-chicken or mouse Cy3-conjugated secondary antibody (Chemicon, 1:1000) for 30 min. Cells were then washed quickly five times with 100 mM Hepes ϩ 3% BSA and fixed with 4% paraformaldehyde for 5 min at room temperature. Coverslips were mounted and visualized using epifluorescence microscopy.
Proteolysis of mGluR5a-transfected COS7 Cell Membranes-24 -36 h post-transfection, cells plated on 100 mm poly-D-lysine, tissue culture treated plates were washed twice with 10 ml of 250 mM sucrose, 10 mM TEA-acetate pH 7.4, 1 mM EDTA-TEA, pH 8. Cells were then scraped into 800 l of hypotonic lysis buffer (10 mM TEA-acetate pH 7.4, 1 mM EDTA-TEA, pH 8) and allowed to stand on ice for 5-10 min. Cells were homogenized by sending through 23-and 26-gauge needles eight times each. Sucrose was added to a final concentration of 250 mM, and the homogenate was spun at 1020 ϫ g for 10 min to pellet nuclei and debris. The supernatant was placed over a 0.5 M sucrose cushion and spun in a TLA100.2 rotor at 60,000 rpm for 10 min. The membrane pellet was washed with 1 ml of enzyme buffer (120 mM NaCl, 50 mM Tris-Cl, pH 8, 20 mM CaCl 2 ) and recentrifuged for 5 min. The pellet was resuspended in enzyme buffer and 1-5 g/ml Asp-N (Roche Applied Science) was added. The reactions were allowed to proceed for 1-2 h at 25°C. Asp-N digests were stopped by adding 50 mM EDTA-Na, pH 8. An equal volume of 2ϫ sample buffer (100 mM Tris-Cl, pH 6.8, 20% glycerol, 4% SDS, 100 mM dithiothreitol, 0.02% bromphenol blue) was added to the reactions and an aliquot loaded for SDS-PAGE. This protocol minimized post-solubilization proteolysis as determined by control experiments where reactions were immediately terminated after protease addition.
Proteins were separated on 7% SDS-polyacrylamide gels, which were then equilibrated in 1ϫ Towbin Buffer ϩ 0.01% SDS. Immobilon-polyvinylidene difluoride transfer membrane (Millipore, pore size 0.45 M) was hydrated in 100% methanol prior to use, and proteins were transferred at a constant voltage of 75 V overnight using a BioRad wet transfer apparatus. Membranes were blocked at room temperature for 1 h in 5% milk in TBST, and then incubated in primary antibody (rat anti-HA, 1:1000, Roche Applied Science) for 1 h at room temperature.
Membranes were then rinsed 4 ϫ 15 min in TBST and incubated for 1 h at room temperature in secondary antibody solution (goat anti-rat conjugated to horseradish peroxidase, 1:10,000 in 5% milk). Membranes were then rinsed 4 ϫ 15 min in TBST prior to visualization of immunoreactive bands using West Pico Supersignal ECL substrate (Pierce) and Kodak BioMax-MR film.
RESULTS

N-Glycosylation
Site Analysis-N-glycosylation occurs only on extracellular domains of proteins. Therefore, one common method for the determination of membrane topology is the analysis of native and engineered glycosylation sites. An analysis of the mGluR5 protein sequence reveals 6 possible Nglycosylation NX(S/T) consensus sites (28) (Fig. 2A) . Five of these sites reside on the large N-terminal domain, which is known to be extracellular. One additional site exists in the putative 2nd extracellular loop (e2). We constructed several mutants of mGluR5 in which all but one of the native glycosylation sites was mutated, and analyzed the possible glycosylation of these sites by comparing gel mobility shifts of these proteins compared with wild-type mGluR5 expressed in COS7 cells. A mutant in which all of the native glycosylation sites had been mutated (⌬NG) showed a large mobility shift compared with wild-type mGluR5 (Fig. 2B ). These 6 mutations accounted for all of the apparent N-glycosylation, as treatment with tunicamycin, which prevents N-glycosylation, caused no apparent mobility shift in the ⌬NG mutant (Fig. 2C) . Interestingly, when each of the glycosylation sites was examined individually, only mutation of Asn-444 (native glycosylation site no. 5, or NG5), showed any apparent mobility shift compared with ⌬NG, suggesting that Asn-444 accounts for all of the detectable native N-glycosylation in mGluR5. 
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lacks all glycosylation consensus sites except the Asn-733 NG6 site) and grew these cultures in the absence or presence of tunicamycin. We could not detect any mobility shift in response to inhibiting glycosylation for the NG6 construct, although tunicamycin caused a pronounced mobility shift for the Asn-444 NG5 construct (Fig. 2B) . Taken together, these results suggest that Asn-444, but not Asn-733 in mGluR5a is glycosylated in COS7 cells. Similar results were obtained when these constructs were expressed in HEK293T cells (data not shown).
To test whether the hydrophilic loops between the predicted transmembrane domains were in the predicted orientation, a number of ectopic n-glycosylation consensus sequences (NX(S/ T)) were introduced into the ⌬NG construct by mutagenesis. These included the introduction of two consensus sites simultaneously in i1, two simultaneously in e1, one individually in e2, and 3 simultaneously in the proximal region of the Cterminal tail (for positions see Fig. 7 ). None of the ectopic glycosylation consensus mutants resulted in any detectable mobility shift compared with the ⌬NG mutant, and no shifts in the ectopic glycosylation mutants could be detected when comparing the constructs in the absence and presence of tunicamycin, suggesting that these sites are not significantly glycosylated (data not shown). Since not all extracellularly located glycosylation consensus sequences are glycosylated, the absence of glycosylation is not completely surprising and does not contribute to determining membrane topology. Nonetheless, these experiments clearly identify Asn-444 as the major Nlinked glycosylation site in mGluR5a.
Analysis of mGluR5a-Lactamase Fusion Proteins in Escherichia coli-
The membrane topology of several prokaryotic and eukaryotic membrane proteins has been studied in bacteria typically using fusions to alkaline phosphatase or ␤-galactosidase. More importantly, the topology of canonical ␤-adrenergic and the V2 vasopressin GPCRs has been determined in E. coli using similar approaches (29, 30) . Thus, studying mGluR topology in bacteria allows a direct comparison to established 7TM GPCRs.
We fused a series of truncated mGluR5a proteins to ␤-lactamase, which allows for simple determination of lactamase activity and export by testing for ampicillin resistance. At high cell densities, bacteria bearing any form of lactamase, regardless of export, can grow through the provision of lactamase activity from neighboring lysed bacteria. However, at low cell densities, only bacteria with lactamase exported to the periplasmic space can survive by degrading ampicillin before it reaches the cell wall synthesis apparatus. Thus, bacteria transformed with mGluR5a-lactamase fusion constructs where the lactamase moiety has been exported to the periplasm grow at most dilutions, while those where functional lactamase protein remains in the cytoplasm only grow at higher cell densities. Bacteria with non-functional lactamase, such as empty pET28a vector or constructs with lactamase "sandwiched" in-frame within mGluR5, do not grow at all (data not shown). Using this system, it appears that constructs after i2 behave as predicted by the 7TM model. However, constructs before i2 appear inverted with i1 being exported to the periplasm and e1 remaining cytoplasmic (Fig. 2) . While this may suggest an unexpected topology, an alternative hypothesis is that the N-terminal domain fails to be exported without TM3 and/or i2. A similar phenomenon occurs with ␤-adrenergic receptors (29) . Thus, TM1 and TM2 appropriately traverse the membrane, but the N-terminal domain remains cytoplasmic. In support of this notion, the mGluR5 N-terminal domain (without any transmembrane domains) fusion fails to export lactamase (Fig. 3) .
Analysis of mGluR5a Fusion Proteins in Mammalian CellsWhile the prokaryotic studies found that the topology and folding behavior of mGluR5a mimicked 7TM ␤-adrenergic receptors, we wanted to verify these findings in mammalian cells. We created similar mGluR5a fusion proteins with EGFP and expressed them in COS7 cells. Live immunostaining of these cells with anti-GFP antibody was used to determine whether EGFP was translocated extracellularly in these constructs. However, absent immunoreactivity may be due either to a cytoplasmic EGFP or an extracellular EGFP that fails to reach the surface membrane. To confirm surface expression, we also conducted immunostaining against an N-terminal FLAG (DYKDDDK) tag. Several constructs targeted to the surface appropriately and confirmed the locations of i1, e1, e2, and the C-terminal domains as predicted by the 7TM topology model (Fig. 4, B and C) . Some of these fusion constructs did not reach the surface and thus no conclusions could be made regarding i2, i3, and e3 (Fig. 4, B and C) . All constructs exhibited positive staining for anti-FLAG and anti-GFP after membrane permeabilization with 0.2% Triton X (data not shown).
We attempted to achieve surface expression by creating "sandwich" constructs where EGFP was inserted in-frame at each hydrophilic loop of full-length mGluR5a. Several membrane topology studies have utilized this approach of inserting "reporter" epitopes. Surprisingly, only the construct with EGFP inserted at i2 surface expressed and the absence of anti-EGFP immunoreactivity confirmed its cytoplasmic location ( Fig. 4D ; non-surface-expressing construct data not mGluR Topologyshown). Similar results were also obtained with FLAG and HA tag insertions (data not shown).
Taken together, the live immunostaining of EGFP-and FLAG-tagged mGluR5 shown in Fig. 4 have confirmed the cytoplasmic localization of the i1 and i2 loops as well as the C-terminal tail. Further, these results confirm the extracellular localization of e1 and e2 loops. The lack of surface expression of all constructs tested with fusions in the i3 and e3 loops made it apparent that a successful strategy to conclusively study mGluR5 fusion protein topology must be independent of targeting and surface expression. To do this, we conducted Asp-N protection assays of truncated mGluR5a fusion proteins, where the C-terminal domain of mGluR5a itself (amino acids 869-stop) was fused at various points along mGluR5. The construct names (above the diagrams) indicate the location of the EGFP fusion: i1, 1st intracellular loop; e1, 1st extracellular loop; i2, 2nd intracellular loop; e2, 2nd extracellular loop; i3, 3rd intracellular loop; e3, 3rd extracellular loop; C-term, C-terminal fusion. Panel B shows the accessibility of the GFP epitope to an extracellularly applied anti-EGFP antibody (␣-GFP). Top panels, EGFP fluorescence; center panels, EGFP immunoreactive cells when ␣-GFP antibody is applied to live, intact cells; lower panels, overlay of the two images. Panel C shows the surface expression of the constructs, as observed by the accessibility of the N-terminal FLAG tag to the extracellular milieu, and thus to an anti-FLAG antibody (␣-FLAG). Top panel, EGFP fluorescence; center panel, FLAG immunoreactivity when the ␣-FLAG antibody is applied to live, intact cells; lower panels, overlay of the two images. Note that the i2, i3, and e3 constructs do not appropriately target to the cell surface, while the other constructs do. Panel D shows on the left panel the schematic of the in-frame fusion of EGFP in the 2nd intracellular loop (at amino acid 688), and the location of the N-terminal FLAG tag. The right panels show ␣-GFP and ␣-FLAG staining similar to that shown in panel C. Note that this construct is surface-expressed, but shows no GFP staining, indicating intracellular localization of the EGFP tag.
This approach utilizes the parent construct shown in Fig. 5B , which bears a HA epitope tag inserted immediately after the signal peptide at amino acid 22 (mGluR5-HA). This extracellular epitope (at the identical site to the FLAG tag used in Fig.  4 ) is used in Western blots following Asp-N protease treatment of vesicles prepared from COS7 cells expressing mGluR5-HA and various mutants. Vesicles are treated with Asp-N, which will cleave the protein at accessible Asp (D) residues. Vesicle preparations result in vesicles of both inside-out and outsideout orientations. In this approach, only mGluR5-HA from vesicles in the inside-out orientation (with the N-terminal HA epitope protected inside the vesicle) will be visible on anti-HA Western blots (see Fig. 5A ). Furthermore, epitopes that lie in a "cis" orientation relative to the HA tag will be protected, while those lying in a "trans" orientation with respect to the HA tag will be susceptible to Asp-N proteolysis.
Asp-N proteolysis of the full-length mGluR5a protein resulted in two major protected bands (Fig. 5C, arrows) . Mutagenesis of Asp residues to Glu mapped Asp-848 as the smallest cleavage product (Fig. 5C) . Thus, no Asp residues N-terminal to TM7 are accessible to Asp-N cleavage, suggesting that Asp-605, which resides in i1, is not accessible, likely due to its proximity to the membrane. In addition, there are two additional Asp residues in the predicted heptahelical regions of mGluR5. These are Asp-717 and Asp-721, both of which reside in the predicted e2 domain. While Asp-717 probably lies too close to the membrane to be accessible to Asp-N (as was the case for Asp-605), the lack of cleavage of Asp-721 suggests that this domain is either extracellular or folded in a way not accessible to Asp-N. Furthermore, a very sensitive Asp-N site exists C-terminal to D848 (Fig. 5C, small arrow) . Thus, fusion constructs where the mGluR5a C-terminal tail lies in a "trans" configuration to the extracellularly located N-terminal HA tag will be proteolyzed, while those lying in a "cis" conformation will be protected along with the tag. Using this strategy, we found a clear alternating pattern of cytoplasmic to extracellular tags beginning with i1 through e3 (Fig. 6) . Slight reservation exists for TM5 (i3). The fusion construct with its junction in i3 appeared to show both patterns with a proteolyzed fragment and a protected full-length fragment. A reasonable interpretation of this finding is that TM5 is capable of traversing the membrane, but that this conformation is not significantly energetically favorable in an artificially truncated fusion protein. In agreement with this interpretation, studies have shown that certain fusion protein joint positions or truncations may result in equivocal results for cytoplasmic domains (31) . Taken together, the eukaryotic fusion protein studies confirm the prokaryotic studies and consistently uphold the 7TM topological model for mGluR5a as shown in Fig. 7 .
DISCUSSION
Previous studies had clearly shown the extracellular and intracellular localization of the mGluR N and C termini, respectively (4) . Although data suggested that putative intracellular domains participate in G-protein coupling, no studies had systematically addressed the transmembrane domain orientation of the heptahelical domain of mGluRs.
We initiated our study of mGluR topology with basic topological modeling and found that unlike rhodopsin, the models do not predict with high probability that mGluRs possess seven transmembrane domains. Both hydrophobicity and statistical models actually suggest that the third putative transmembrane domain may not traverse the membrane (Fig. 1) . This led us to systematically test the ability of each putative transmembrane domain to span the membrane primarily utilizing a series of truncated fusion constructs common to topological analysis of transmembrane proteins. Although each approach on its own did not definitively confirm every transmembrane domain, each transmembrane domain and the location of an interspersed hydrophilic loop was confirmed by at least one experimental paradigm. The first and second transmembrane domains, the first cytoplasmic loop (i1), and the first extracellular loop (e1) were definitively identified by the truncated GFP fusion constructs and the Asp-N proteolysis with suggestive evidence from the lactamase studies assuming the N terminus fails to translocate without the first three transmembrane domains. The third transmembrane domain and the second intracellular loop (i2) were localized by the lactamase studies, the GFP in-frame insertion construct, and the Asp-N proteolysis experiment. The lactamase fusion constructs, the truncated GFP fusion protein, and the Asp-N proteolysis paradigm delineated the fourth transmembrane domain and the second extracellular loop (e2). The fifth transmembrane domain and third intracellular domain were definitively confirmed by the lactamase studies with suggestive evidence from the Asp-N proteolysis studies. The lactamase fusion studies and the Asp-N proteolysis experiments delineated the sixth transmembrane domain and third extracellular loop (e3). Finally, the seventh transmembrane domain and intracellular C-terminal domain were confirmed with the lactamase studies, truncated GFP fusion protein studies, and Asp-N proteolysis of full-length mGluR5 with a protease accessible site at Asp848. Thus, while single experimental approaches may leave significant doubt, we feel a holistic view of these data is supportive of a seven transmembrane domain topology.
The selective glycosylation at the native site, Asn-444, and the inability to detect any significant glycosylation in the extracellular loops, e1 and e2, with ectopically introduced sites were initially surprising, but in retrospect may have been partially predictable. Overall, only about one-third of NX(S/T) glycosylation consensus sites are significantly glycosylated (28) . A small minority of the non-glycosylated consensus sites may be predicted simply based on sequence with prolines either between the Asn and the Ser/Thr or after the Ser/Thr, heavily diminishing glycosylation (32) . Unfortunately, the great majority of consensus sites are not glycosylated due to unknown, complex protein interactions between the nascent protein and ER glycosylation machinery. However, some empirical findings may allow for some prediction concerning glycosylation. In general, it has been found that glycosylation occurs less frequently as one moves C-terminally along the protein sequence (32) . Specifically, in regards to transmembrane glycoproteins, glycosylation appears to be more likely when a consensus site is more than 10 amino acids away from a transmembrane domain, when the extracellular loop is more than 30 amino acids, and when the extracellular domain is the first to contain consensus sites. In addition, most transmembrane glycoproteins FIG. 7 .
Topological profile of mGluR5. The confirmed seven transmembrane domain topology of mGluR5 is shown along with the location of all of the manipulations made in the present study. The site of introduction of N-terminal FLAG and HA tags is shown by the green triangle (amino acid 22). Sites of inserted SalI restriction sites are indicated by the blue circles. These correspond to amino acid 608 in i1, amino acid 641 in e1, amino acid 688 in i2, amino acid 721 in e2, amino acid 769 in i3, amino acid 799 in e3, and amino acid 869 in the C-terminal tail. Unused native or ectopically introduced glycosylation sites are indicated by the purple and green symbols, respectively, and the glycosylated native site at Asn-444 is indicated by the red symbol. The identified Asp-N cleavage site at Asp-848 is indicated in pink.
have a single glycosylated extracellular domain (33) . Based on these empirical "rules," one would predict that the sixth native glycosylation site in e2 would not be glycosylated and that one or more of the five consensus sites in the N-terminal domain would be glycosylated. While the data support this prediction, it is surprising that the most C-terminal consensus site, Asn-444, appears to be the predominant glycosylation site, which is not consistent with the predicted drop in glycosylation observed with C-terminal progression. In regards to the ectopic glycosylation sites placed in e1 and e2, the short loop size less than 30 amino acids with e1 predicted to be 6 amino acids and e2 predicted to be 23 amino acids and the inability to place any ectopic sites 10 amino acids from a transmembrane domain in e1 predicts a very low probability of glycosylation despite the removal of all native glycosylation consensus sequences. Even in cases where the introduction of ectopic glycosylation sites has proven successful, adjacent sites introduced in the same extracellular loops are frequently not glycosylated (34) . The reason for this is not clear.
Although the mGluRs share no sequence homology to family A or B GPCRs, they do appear to share a common membrane topology. This suggests a functional necessity for the heptahelical structure. Others have noted that although the family C GPCRs do not share sequence homology with family A or B GPCRs, there are important structural similarities. For example, there are two cysteines required for interconnecting the e2 loop with the extracellular surface of transmembrane domain 3 in other GPCRs, and these cysteines appear to be conserved in the mGluRs (4). In addition, there are a number of compounds that act as antagonists of mGluRs that exert their effects through interactions with the membrane domains. Mutational analysis combined with modeling of the heptahelical domain of mGluRs based on the known structure of the analogous domain in rhodopsin revealed a binding pocket that explains the effect of these antagonists (35, 36) . The present results strongly suggest that mGluRs have a seven transmembrane domain topology and add credence to the approach of using rhodopsin for molecular modeling studies of mGluRs.
